Zurex PharmAgra Overview

  • Founded
  • 2011
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • 2ndary - Private

Zurex PharmAgra General Information


Developer of life science technology designed to upgrade animal health through veterinary surgical settings. The company's technology is formulated to sanitize and protect teats from mastitis-causing organisms, enabling clients to avail better technology to safeguard their animals' teat tissue from harsh environmental conditions.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Services
Other Industries
Parent Company
Primary Office
  • 2113 Eagle Drive
  • Middleton, WI 53562
  • United States
+1 (608) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zurex PharmAgra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 00.000 Completed Generating Revenue
2. Early Stage VC 17-Jul-2013 00000 00.000 Completed Generating Revenue
1. Debt - General 01-Mar-2012 $1M $1M Completed Generating Revenue
To view Zurex PharmAgra’s complete valuation and funding history, request access »

Zurex PharmAgra Executive Team (5)

Name Title Board Seat Contact Info
Carmine Durham President, Chief Executive Officer and Board Member
Alex Kasper Chief Financial Officer
R. Andrew Morgan Executive Vice President, Regulatory Affairs and Quality Operations
Robert Truitt Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

Zurex PharmAgra Board Members (5)

Name Representing Role Since
Carmine Durham Self President, Chief Executive Officer and Board Member 000 0000
Gary Tauchen Self Board Member 000 0000
Jason Smith Self Board Member 000 0000
Nicholas Babson Self Board Member 000 0000
Robert Truitt Self Chairman 000 0000
To view Zurex PharmAgra’s complete board members history, request access »